Noile-Immune Biotech is a clinical-stage biopharmaceutical company focused on the development of next-generation CAR-T cell therapies for solid tumors, leveraging its proprietary PRIME technology exclusively licensed from Yamaguchi University. PRIME technology activates not only the administered CAR-T cells but also the patient's endogenous immune cells, offering a differentiated mechanism of action against solid cancers where conventional CAR-T therapies have limited efficacy. The company operates a hybrid business model combining in-house drug discovery pipelines with PRIME technology licensing partnerships to accelerate commercialization and diversify revenue.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →Noile-Immune Biotech is a clinical-stage biopharmaceutical company focused on the development of next-generation CAR-T cell therapies for solid tumors, leveraging its proprietary PRIME technology exclusively licensed from Yamaguchi University. PRIME technology activates not only the administered CAR-T cells but also the patient's endogenous immune cells, offering a differentiated mechanism of action against solid cancers where conventional CAR-T therapies have limited efficacy. The company operates a hybrid business model combining in-house drug discovery pipelines with PRIME technology licensing partnerships to accelerate commercialization and diversify revenue.
Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.
Free Demo (No Time Limit, 10 Companies) →